Ambagon Therapeutics

Ambagon Therapeutics

Biotechnology, 953 St, Daly City, California, Indiana, 94107, United States, 11-50 Employees

ambagontx.com

  • twitter
  • LinkedIn

phone no Phone Number: 14*********

Who is AMBAGON THERAPEUTICS

Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagons platform ...

Read More

map
  • 953 Indiana St, Daly City, California, 94107, United States Headquarters: 953 Indiana St, Daly City, California, 94107, United States
  • 2020 Date Founded: 2020
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 7389

checked-icon Does something look wrong? Fix it. | View contact records from AMBAGON THERAPEUTICS

Ambagon Therapeutics Org Chart and Mapping

Employees

Nancy Pryer

Chief Scientific Officer

Peipei Li

Principal Scientist, Research Informatics and Bioinformatics Team Lead

Tanja Meyer

VP & Head, Corporate Strategy & Business Development

Michelle Pazmino

Senior Research Associate

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Ambagon Therapeutics

Answer: Ambagon Therapeutics's headquarters are located at 953 St, Daly City, California, Indiana, 94107, United States

Answer: Ambagon Therapeutics's phone number is 14*********

Answer: Ambagon Therapeutics's official website is https://ambagontx.com

Answer: Ambagon Therapeutics's revenue is $5 Million to $10 Million

Answer: Ambagon Therapeutics's SIC: 7389

Answer: Ambagon Therapeutics has 11-50 employees

Answer: Ambagon Therapeutics is in Biotechnology

Answer: Ambagon Therapeutics contact info: Phone number: 14********* Website: https://ambagontx.com

Answer: Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagons platform approach will open opportunities to address major unmet clinical needs beyond oncology.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access